June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
One year outcome of treat and extend regimen of aflibercept for polypoidal choroidal vasculopathy
Author Affiliations & Notes
  • Tomoko Tamachi
    Ophthalmology and Visual Sciences, Osaka City University Graduate School of Medicine, Osaka, Osaka, Japan
  • Takeya Kohno
    Ophthalmology and Visual Sciences, Osaka City University Graduate School of Medicine, Osaka, Osaka, Japan
  • Akika Kyo
    Ophthalmology and Visual Sciences, Osaka City University Graduate School of Medicine, Osaka, Osaka, Japan
  • Manabu Yamamoto
    Ophthalmology and Visual Sciences, Osaka City University Graduate School of Medicine, Osaka, Osaka, Japan
  • Natsuko Oishi
    Ophthalmology and Visual Sciences, Osaka City University Graduate School of Medicine, Osaka, Osaka, Japan
  • Jyunji Asai
    Ophthalmology and Visual Sciences, Osaka City University Graduate School of Medicine, Osaka, Osaka, Japan
  • Shinsuke Ataka
    Ophthalmology and Visual Sciences, Osaka City University Graduate School of Medicine, Osaka, Osaka, Japan
  • Ayako Yasui
    Ophthalmology and Visual Sciences, Osaka City University Graduate School of Medicine, Osaka, Osaka, Japan
  • Akira Cho
    Shiraniwa Hosp, Ikoma, Japan
  • Michiko Hirabayashi
    Shiraniwa Hosp, Ikoma, Japan
  • Kunihiko Shiraki
    Ophthalmology and Visual Sciences, Osaka City University Graduate School of Medicine, Osaka, Osaka, Japan
  • Footnotes
    Commercial Relationships   Tomoko Tamachi, None; Takeya Kohno, None; Akika Kyo, None; Manabu Yamamoto, None; Natsuko Oishi, None; Jyunji Asai, None; Shinsuke Ataka, None; Ayako Yasui, None; Akira Cho, None; Michiko Hirabayashi, None; Kunihiko Shiraki, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 885. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Tomoko Tamachi, Takeya Kohno, Akika Kyo, Manabu Yamamoto, Natsuko Oishi, Jyunji Asai, Shinsuke Ataka, Ayako Yasui, Akira Cho, Michiko Hirabayashi, Kunihiko Shiraki; One year outcome of treat and extend regimen of aflibercept for polypoidal choroidal vasculopathy. Invest. Ophthalmol. Vis. Sci. 2017;58(8):885.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose :
To evaluate one year outcome of intravitreal injections of aflibercept using treat and extend regimen for polypoidal choroidal vasculopathy (PCV).

Methods :
62 treatment-naive PCV patients were retrospectively reviewed. The initial injection interval was 5 weeks. Three monthly or more aflibercept injections were administered until obtaining dry retina and the injection interval was extended by two weeks up to maximum 13 weeks. When a fluid recurrence occurred, the injection interval was shortened to the initial 5 weeks. Polypoidal vessels (polyps) were evaluated on indocyanine green angiography.

Results :
Mean log MAR visual acuity (VA) improved significantly from 0.25 at baseline to 0.19 at 12 months (p=0.032) in 61 eyes. Mean central foveal thickness was significantly lower at 12 months (219.6 µm) than at baseline (345.1 µm, P<0.001). The mean number of aflibercept injections to obtain dry retina was 3.5 (3-10) and the total number of the injections was 7.5 (6-10) during one year. The macula was dry in 53 (85.5 %), 48 (77.4 %) and 47 eyes (75.8 %) at 3, 6, and 12 months respectively. 24 eyes (38.7 %) had recurrences when the injection interval was extended. Eyes with recurrences had significantly lower rates of the complete occlusion of the polyps at 3 months (p=0.023) and at 12 months (p<0.001) than those without recurrences.

Conclusions :
Treat and extend regimen of aflibercept showed favorable visual and anatomical outcomes in PCV patients at one year. Presence or absence of complete polyp-regression may be a factor for predicting a recurrence during the injection-interval extension.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×